The US Food and Drug Administration (FDA) has announced a new safety warning for GLP-1 medications after identifying a potential association with a rare eye condition that can cause permanent vision loss.
The warning concerns non-arteritic anterior ischemic optic neuropathy (NAION), a condition that affects blood flow to the optic nerve. The FDA is requiring manufacturers of GLP-1 medications to update their product safety information.
The review follows reports of NAION cases among patients using popular medications, including semaglutide-based treatments.
An FDA analysis of more than 125 clinical trials found approximately six cases per 100,000 patients taking GLP-1 medications for at least a year, compared with fewer than four cases per 100,000 in comparison groups.
The warning is particularly important as GLP-1 medications become increasingly popular for diabetes management and weight loss across the United States.
Health professionals are being encouraged to discuss potential risks with patients and advise anyone experiencing sudden vision changes to seek urgent medical assessment.
The development highlights the importance of continued medication safety monitoring as the market for obesity and diabetes treatments expands.
Comments (0)
Sign in to join the conversation.